A meta-analysis of HIV-negative
gay men’s sexual behaviour and HIV incidence rate in four HIV prevention studies,
presented earlier this month at the 19th Conference on Retroviruses and
Opportunistic Infections (CROI), has found that attempting to ‘serosort’ by
restricting unprotected sex to partners known to be HIV negative does have efficacy
as an HIV prevention strategy, when compared with using no strategy at all.
Serosorting is,
however, considerably less effective in reducing the chances of acquiring HIV than four other strategies: 100% condom use, monogamy, only having insertive sex, or ‘seropositioning’
(only taking the bottom role with partners known not to have HIV and being top
with partners of positive or unknown status). Interestingly, 100% condom use was the least effective of these other four strategies.
‘Seroadaptive’
behaviours include any method of attempting to reduce the risk of HIV
acquisition or transmission by altering one’s sexual behaviour according to the
HIV status of partners. The term ‘serosorting’ has been used in various different
ways. Most commonly, it means restricting unprotected anal sex to partners known
to have the same HIV status as yourself. When unprotected sex between
HIV-negative men is confined to a primary relationship, with condoms used in all
other encounters, this has been called ‘negotiated safety’.
While some studies have
found serosorting in HIV-negative men to be effective, others have not.
Attempted serosorting by HIV-negative people has an inherent drawback that serosorting
by HIV-positive people lacks: people can only be certain of their status up to
the first time they risk exposure to HIV after their last negative HIV test.
Research indicates that a large minority of people in high-risk communities who
assume they are HIV negative in fact have HIV, and that a large proportion of
men who ‘know’ their partner’s HIV status have, in fact, tried to guess it.
The meta-analysis
Nonetheless,
though serosorting is fallible, a recent meta-analysis of studies presented at
CROI found that serosorting halved the likelihood of acquiring HIV compared to
having no strategy at all.
The study pooled
behavioural data and HIV incidence rates from four different studies in gay
men:
- The
HIVNET 001 Vaccine Preparedness Study (VPS), an observational study that took
place in eight cities in the US between 1995 and 1997.
- VAX 004, the
first phase III efficacy trial of a candidate HIV vaccine, which took place at
61 sites in the US, Canada and the Netherlands between 1998 and 2001.
There were a total of 12,705 HIV-negative gay men from North
America included in these trials, of whom 663 (5%) acquired HIV.
By analysing the results of sexual behaviour
questionnaires, the researchers in the present study divided respondents' sexual behaviour into a risk hierarchy, running from what they hypothesised would be the
safest option to the most risky. 'Hierarchy' means that only those not practising the first option were assessed for their use of the second option, only those not practising the second option assessed for their use of the third, and so on.
The options were:
No
unprotected anal sex: either no anal sex at all or 100% condom use (47% of the
group)
Monogamy:
has unprotected anal sex, but only within a monogamous, seroconcordant relationship (11%)
- Top
only: only ever takes the insertive role in unprotected anal sex, regardless of condom use
or partner’s serostatus (10%)
- Serosorting:
has unprotected anal sex but only with partners thought to be HIV negative (8%)
- Seropositioning:
unprotected receptive anal sex only with negative partners, always insertive with partners
of positive or unknown HIV status (3%)
- Risky
sex: has unprotected sex with no risk reduction strategy (21%).
Throughout the studies, adoption of these strategies
was fluid and inconsistent: only 23% of men in the studies maintained one
specific strategy throughout the study.
Findings
The four study groups were in some ways very similar
and in others very different. The average age was 34, with little variation
between studies, and the groups were predominantly white (78%), with only 6%
African American.
In other ways they were very different: EXPLORE was
recruited from a ‘high-risk’ group of gay men and STEP from a largely low-risk
group. One in six of the men had been celibate or monogamous in the last six
months, but this varied from 8% in EXPLORE to 51% in STEP; 60% in EXPLORE but
only 11% in STEP had had six partners or more in the last six months; 13% of
the men in EXPLORE had used methamphetamine but only 4% in STEP.
All risk reduction strategies helped to curb HIV
infections, but some much more than others – and the safety hierarchy wasn’t
what researchers had expected.
HIV annual incidence in people with no safer-sex
strategy was 2.95%. In serosorters, it was 1.44% (a 51% reduction in HIV
incidence).
After this, the next riskiest thing was 100% condom
use/no anal sex: the seroconversion rate in this group was 0.76% a year (74%
reduction). Seropositioning was about as safe: the incidence rate was 0.73%
(75% reduction).
Men who were ‘top only’ only had an HIV incidence
rate of 0.4% (86% reduction). And the safest option of all was old-fashioned monogamy; in monogamous men the annual HIV incidence rate was
only 0.25%, a 91.5% reduction in HIV risk.
Studies of serosorting have in the past suffered
from small numbers and wide confidence intervals. Although the validity of the
risk categories and the methodology of individual behavioural
questionnaires may be challenged, this is a large enough meta-analysis to more reliably establish
the risk of different methods. The 74% reduction seen with 100% condom use is
not incompatible with figures arrived at in the relatively few studies of
condom efficacy in gay men: what perhaps is more of a surprise is that having a
trusted, monogamous relationship or being an exclusive top are so much more protective
than this.